ASH 2024 Archives - Medical Conferences

Letter from the Editor

Editor

Prof. Gert Ossenkoppele, Amsterdam UMC, the Netherlands

Meet the Trialist: Prof. Mats Jerkeman on the ALTAMIRA trial

Expert

Prof. Mats Jerkeman, Skane University Hospital and Lund University, Sweden

ASH 2024 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

InMIND: Novel standard-of-care for relapsed or refractory follicular lymphoma?

Presented By

Prof. Laurie Sehn, University of British Columbia, Canada

High CR rates for novel CAR T-cell therapy in follicular lymphoma and DLBCL

Presented By

Dr Jing-Zhou Hou, University of Pittsburgh Medical Center, PA, USA; Dr Sameh Gaballa, Lee Moffitt Cancer Center, FL, USA

Excellent CR rates for venetoclax plus pola-R-CHP in BCL2-positive DLBCL

Presented By

Dr Catherine Diefenbach, NYU Langone Health, NY, USA

ATALANTA-1: Promising data for novel CAR T-cell therapy

Presented By

Prof. Marie José Kersten, Amsterdam University Medical Center, the Netherlands

ZUMA-5: Curative potential of axi-cel in follicular lymphoma

Presented By

Prof. Sattva Neelapu, MD Anderson Cancer Center, TX, USA

Can we omit auto-SCT in patients with mantle cell lymphoma with undetectable MRD post-induction?

Presented By

Dr Timothy Fenske, Medical College of Wisconsin, WI, USA

Quizartinib maintenance therapy crucial for FLT3-ITD-positive AML

Presented By

Prof. Mark Levis, Johns Hopkins University, MD, USA

Revumenib combination therapy associated with high response rates in relapsed/refractory AML

Presented By

Dr Ghayas Issa, MD Anderson Cancer Center, TX, USA

Venetoclax plus azacitidine in young patients with AML

Presented By

Dr Daniel Pollyea, University of Colorado, CO, USA

Promising results for ivosidenib-based triplet therapy in IDH1-mutated malignancies

Presented By

Dr Jennifer Marvin-Peek, MD Anderson Cancer Center, TX, USA

CPX-351 outperforms FLAG-Ida in AML/MDS and MDS-related mutations

Presented By

Dr Priyanka Mehta, University Hospitals Bristol NHS Foundation Trust, UK

High MRD-negativity rates for venetoclax plus ‘7+3’ chemotherapy in newly diagnosed AML

Presented By

Dr Ioannis Mantzaris, Montefiore Medical Center, NY, USA

Findings from phase 3 uproleselan study in AML not all negative

Presented By

Prof. Daniel DeAngelo, Dana-Farber Cancer Institute, MA, USA

Menin inhibitors on the rise in KMT2Ar acute leukaemia

Presented By

Dr Ibrahim Aldoss, City of Hope, CA, USA

New standard-of-care for paediatric B-cell ALL

Presented By

Dr Rachel Rau, University of Washington, WA, USA

KCRd offers overall survival benefit over CRd in newly diagnosed MM

Presented By

Dr Charlotte Pawlyn, Institute of Cancer Research, UK

AQUILA: Early intervention with daratumumab extends survival in smouldering MM

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Emerging mezigdomide-based options for heavily pre-treated MM

Presented By

Prof. Luciano Costa, University of Alabama at Birmingham, AL, USA

IFM2017-03: Daratumumab therapy fruitful for frail patients with MM

Presented By

Prof. Salomon Manier, University of Lille, France

CEPHEUS: Further support for daratumumab regimens in untreated MM

Presented By

Prof. Sonja Zweegman, Amsterdam University Medical Centre, the Netherlands

Positive trends for etavopivat in sickle cell disease

Presented By

Dr Sophia Delicou, Hippocrates General Hospital, Greece

LUNA 3: Rilzabrutinib meets primary endpoint in ITP

Presented By

Prof. David Kuter, Massachusetts General Hospital, MA, USA

Full-dose or reduced-dose DOACs in high-risk VTE on extended therapy?

Presented By

Prof. Francis Couturaud, Brest University Hospital, France

Allo-SCT improves lives of children with sickle cell anaemia and abnormal cerebral artery velocities

Presented By

Dr Françoise Bernaudin, Centre Hospitalier Intercommunal Creteil, France

PIVOT: Can hydroxyurea improve outcomes in haemoglobin sickle cell disease?

Presented By

Dr Yvonne Dei-Adomakoh, Korle-bu Teaching Hospital, Ghana

ANDROMEDA: Daratumumab-based frontline standard-of-care in AL amyloidosis

Presented By

Dr Efstathios Kastritis, University of Athens, Greece

Medical Conferences

ASH 2024

Table of Contents

Featured articles

Letter from the Editor

Meet the Trialist: Prof. Mats Jerkeman on the ALTAMIRA trial

ASH 2024 Highlights Podcast

Lymphoma

InMIND: Novel standard-of-care for relapsed or refractory follicular lymphoma?

High CR rates for novel CAR T-cell therapy in follicular lymphoma and DLBCL

Excellent CR rates for venetoclax plus pola-R-CHP in BCL2-positive DLBCL

ATALANTA-1: Promising data for novel CAR T-cell therapy

ZUMA-5: Curative potential of axi-cel in follicular lymphoma

Can we omit auto-SCT in patients with mantle cell lymphoma with undetectable MRD post-induction?

Leukaemia

Quizartinib maintenance therapy crucial for FLT3-ITD-positive AML

Revumenib combination therapy associated with high response rates in relapsed/refractory AML

Venetoclax plus azacitidine in young patients with AML

Promising results for ivosidenib-based triplet therapy in IDH1-mutated malignancies

CPX-351 outperforms FLAG-Ida in AML/MDS and MDS-related mutations

High MRD-negativity rates for venetoclax plus ‘7+3’ chemotherapy in newly diagnosed AML

Findings from phase 3 uproleselan study in AML not all negative

Menin inhibitors on the rise in KMT2Ar acute leukaemia

New standard-of-care for paediatric B-cell ALL

Multiple Myeloma

KCRd offers overall survival benefit over CRd in newly diagnosed MM

AQUILA: Early intervention with daratumumab extends survival in smouldering MM

Emerging mezigdomide-based options for heavily pre-treated MM

IFM2017-03: Daratumumab therapy fruitful for frail patients with MM

CEPHEUS: Further support for daratumumab regimens in untreated MM

Non-Malignant Haematology

Positive trends for etavopivat in sickle cell disease

LUNA 3: Rilzabrutinib meets primary endpoint in ITP

Full-dose or reduced-dose DOACs in high-risk VTE on extended therapy?

Allo-SCT improves lives of children with sickle cell anaemia and abnormal cerebral artery velocities

PIVOT: Can hydroxyurea improve outcomes in haemoglobin sickle cell disease?

Miscellaneous

ANDROMEDA: Daratumumab-based frontline standard-of-care in AL amyloidosis